Amicus Therapeutics, Inc.
FOLD
주식 순위
#3706
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
주가
$14.49
마지막 동기화: 2026-04-27
시가총액
$4.55B
변동 (1일)
0.00%
변동 (1년)
71.68%
국가
US
거래 Amicus Therapeutics, Inc. (FOLD)
카테고리
Healthcare
Amicus Therapeutics, Inc. (FOLD)의 매출
Dec 2025 기준 매출 TTM: $634.21M
Amicus Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $634.21M입니다. 2023년에 회사는 $399.36M의 수익을 올렸으며 이는 2022년의 $329.23M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Amicus Therapeutics, Inc.의 수익 기록 (2003 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $634.21M | 20.05% |
| 2024 | $528.30M | 32.29% |
| 2023 | $399.36M | 21.30% |
| 2022 | $329.23M | 7.76% |
| 2021 | $305.51M | 17.11% |
| 2020 | $260.89M | 43.16% |
| 2019 | $182.24M | 99.72% |
| 2018 | $91.25M | 147.08% |
| 2017 | $36.93M | 644.86% |
| 2016 | $4.96M | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $1.22M | 237.19% |
| 2013 | $363.00K | -98.03% |
| 2012 | $18.41M | -14.10% |
| 2011 | $21.43M | 2,224.73% |
| 2010 | $922.00K | -98.57% |
| 2009 | $64.36M | 330.00% |
| 2008 | $14.97M | 738.96% |
| 2007 | $1.78M | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 1,890.56% |
US
|
|
| $2.23B | 251.30% |
US
|
|
| $15.74B | 2,382.51% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 849.42% |
NL
|
